Kamada

KMDA

Market cap $471M

REHOVOT, Israel, and HOBOKEN, N.J., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that the Company has been awarded an extension of an existing tender from the Canadian Blood Services (CBS) for the supply of four specialty plasma-derived  products, WINRHO®, HEPAGAM®, CYTOGAM®, and VARIZIG®, for an additional two years. Valued at a range of $10-$14 million, the award secures ongoing sales of those products in the Canadian market between Q2-26 and Q1-28. The four commercial products are approved by Health Canada and the U.S. Food and Drug Administration (FDA). CBS manages the Canadian supply of blood products for all Canadian provinces and territories, excluding Quebec.

Kamada Ltd. (NASDAQ: KMDA) on Monday said it will discontinue its Phase 3 InnovAATe trial of Inhaled AAT for Alpha-1 Antitrypsin Deficiency (AATD).

Kamada Ltd. (KMDA) Discusses Discontinuation of Phase 3 Inhaled AAT Clinical Trial and Financial Outlook Transcript

Kamada (KMDA) possesses solid growth attributes, which could help it handily outperform the market.

Kamada Ltd. ( KMDA ) Q3 2025 Earnings Call November 10, 2025 8:30 AM EST Company Participants Amir London - Chief Executive Officer Chaime Orlev - Chief Financial Officer Conference Call Participants Brian Ritchie - Lifesci Advisors, LLC Annabel Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division James Sidoti - Sidoti & Company, LLC Presentation Operator Good morning.

While the top- and bottom-line numbers for Kamada (KMDA) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Kamada (KMDA) came out with quarterly earnings of $0.09 per share, missing the Zacks Consensus Estimate of $0.1 per share. This compares to earnings of $0.07 per share a year ago.

REHOVOT, Israel, and HOBOKEN, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced financial results for the three months and nine months ended September 30, 2025.

Beyond analysts' top-and-bottom-line estimates for Kamada (KMDA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2025.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.